drugset
drugset / Trial / NCT03451916

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

NCT03451916 ↗

Phase 3 Completed 240 enrolled Pluristem Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.

Timeline

Start
2018-07-26
Primary completion
2022-04-29
Completion
2023-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject EMIPLACEL Cell therapy 1.5e+08 cells Intramuscular

Indications

No indication recorded.